secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001937653-23-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q2 2023 net loss narrows 45% to $75.5M; zanidatamab Phase 2b data show 41.3% ORR
--------------------------------------------------------------------------------

- Revenue surged to $42.6M (from $7.4M) on Jazz collaboration; net loss improved 45% YoY to $75.5M.
- Cash and marketable securities $431.4M; runway expected through at least end-2026.
- Zanidatamab Phase 2b BTC results: cORR 41.3%, median DOR 12.9 months, median PFS 5.5 months.
- Next IND candidate ZW220 (NaPi2b-TOPO1i ADC) targeting NSCLC/ovarian cancer; IND filing expected 1H 2025.
- Appointed Carlos E. Campoy to board; reiterated 2023 non-GAAP cash burn guidance $110M-$130M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000026/0001937653-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765323000026/zyme-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001937653-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer